Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

Palbociclib, Metastatic breast cancer, Medicine, Neutropenia, Internal medicine, Fulvestrant, Oncology, Febrile neutropenia, Breast cancer, Cancer, Adverse effect, Chemotherapy, Estrogen receptor